Schwab Charles Investment Management Inc. Buys 7,918 Shares of Supernus Pharmaceuticals, Inc. (SUPN)
Schwab Charles Investment Management Inc. lifted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 203,197 shares of the specialty pharmaceutical company’s stock after acquiring an additional 7,918 shares during the period. Schwab Charles Investment Management Inc. owned 0.40% of Supernus Pharmaceuticals worth $8,758,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sheets Smith Wealth Management bought a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth $378,000. Bank of America Corp DE grew its stake in Supernus Pharmaceuticals by 10.7% during the 1st quarter. Bank of America Corp DE now owns 362,952 shares of the specialty pharmaceutical company’s stock worth $11,361,000 after buying an additional 35,069 shares during the last quarter. MARSHALL WACE ASIA Ltd purchased a new position in Supernus Pharmaceuticals during the 1st quarter worth $468,000. Dimensional Fund Advisors LP grew its stake in Supernus Pharmaceuticals by 3.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,146,040 shares of the specialty pharmaceutical company’s stock worth $35,871,000 after buying an additional 39,033 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust purchased a new position in Supernus Pharmaceuticals during the 2nd quarter worth $17,553,000. 95.38% of the stock is owned by hedge funds and other institutional investors.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) opened at 41.35 on Thursday. Supernus Pharmaceuticals, Inc. has a 52 week low of $17.25 and a 52 week high of $50.05. The company’s 50-day moving average price is $43.88 and its 200 day moving average price is $38.79. The stock has a market capitalization of $2.10 billion, a P/E ratio of 20.86 and a beta of 1.30.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The company had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $68.54 million. Equities research analysts expect that Supernus Pharmaceuticals, Inc. will post $1.04 EPS for the current fiscal year.
In other Supernus Pharmaceuticals news, insider Stefan K.F. Schwabe sold 95,000 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total value of $4,426,050.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 3,709 shares of the firm’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total value of $167,758.07. Following the completion of the sale, the vice president now owns 17,500 shares in the company, valued at $791,525. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 157,444 shares of company stock worth $7,390,810. 6.70% of the stock is owned by insiders.
Several research analysts recently weighed in on SUPN shares. BidaskClub upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Jefferies Group LLC boosted their target price on Supernus Pharmaceuticals from $45.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, June 28th. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a research note on Wednesday, July 5th. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 target price on the stock in a research note on Thursday, July 13th. Finally, Janney Montgomery Scott started coverage on Supernus Pharmaceuticals in a research note on Friday, July 14th. They set a “neutral” rating and a $47.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $47.71.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.